The ROC analysis confirmed that the sensitivity and specificity of TRIB2/MAP3K1 expression were statistically significant, indicating that TRIB2/MAP3K1 expression should be investigated for evaluating the prognosis and therapeutic efficacy in patients with glioma. Here, MAP3K1 is linked to central nervous system cancer.